| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aromatase Inhibitors | 97 | 2021 | 487 | 15.570 |
Why?
|
| Nitriles | 58 | 2017 | 953 | 9.640 |
Why?
|
| Triazoles | 61 | 2017 | 904 | 9.570 |
Why?
|
| Breast Neoplasms | 195 | 2021 | 20827 | 7.010 |
Why?
|
| Androstadienes | 31 | 2021 | 345 | 6.050 |
Why?
|
| Tamoxifen | 51 | 2016 | 981 | 5.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 47 | 2021 | 1523 | 5.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 25 | 2014 | 413 | 4.650 |
Why?
|
| Chemotherapy, Adjuvant | 60 | 2021 | 3480 | 3.260 |
Why?
|
| Postmenopause | 59 | 2020 | 2458 | 2.770 |
Why?
|
| Antineoplastic Agents | 46 | 2017 | 13691 | 2.230 |
Why?
|
| Selective Estrogen Receptor Modulators | 12 | 2017 | 129 | 2.060 |
Why?
|
| Quinazolines | 9 | 2016 | 1356 | 1.810 |
Why?
|
| Enzyme Inhibitors | 19 | 2008 | 3794 | 1.730 |
Why?
|
| Receptors, Estrogen | 31 | 2021 | 2190 | 1.690 |
Why?
|
| Receptor, erbB-2 | 17 | 2016 | 2418 | 1.590 |
Why?
|
| Disease-Free Survival | 39 | 2017 | 6895 | 1.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 40 | 2021 | 11524 | 1.300 |
Why?
|
| Receptors, Progesterone | 16 | 2016 | 1098 | 1.240 |
Why?
|
| Androstenedione | 13 | 2009 | 130 | 1.210 |
Why?
|
| Anticarcinogenic Agents | 7 | 2012 | 253 | 1.150 |
Why?
|
| Uterus | 5 | 2011 | 711 | 1.140 |
Why?
|
| Bone Density | 14 | 2014 | 3460 | 1.140 |
Why?
|
| Estrogens | 18 | 2020 | 1563 | 1.080 |
Why?
|
| National Health Programs | 3 | 2013 | 445 | 1.060 |
Why?
|
| Health Services Accessibility | 9 | 2018 | 5136 | 1.050 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2021 | 9239 | 0.990 |
Why?
|
| Toremifene | 3 | 2009 | 24 | 0.940 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2017 | 255 | 0.940 |
Why?
|
| Breast | 11 | 2021 | 1970 | 0.920 |
Why?
|
| Female | 224 | 2021 | 380020 | 0.910 |
Why?
|
| Neoplasms | 16 | 2020 | 21675 | 0.860 |
Why?
|
| Clinical Trials as Topic | 25 | 2018 | 7908 | 0.820 |
Why?
|
| Health Planning | 2 | 2013 | 237 | 0.800 |
Why?
|
| Latin America | 6 | 2017 | 379 | 0.750 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2018 | 2018 | 0.750 |
Why?
|
| Mexico | 7 | 2020 | 689 | 0.720 |
Why?
|
| Drug Administration Schedule | 20 | 2016 | 4931 | 0.720 |
Why?
|
| Papillomavirus Vaccines | 2 | 2017 | 491 | 0.720 |
Why?
|
| Mammography | 14 | 2021 | 2475 | 0.710 |
Why?
|
| Humans | 262 | 2021 | 743811 | 0.700 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2018 | 320 | 0.700 |
Why?
|
| Early Detection of Cancer | 7 | 2021 | 3089 | 0.690 |
Why?
|
| Imidazoles | 4 | 2011 | 1206 | 0.670 |
Why?
|
| Osteoporosis | 5 | 2014 | 1577 | 0.660 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2018 | 1100 | 0.650 |
Why?
|
| Double-Blind Method | 23 | 2016 | 12020 | 0.650 |
Why?
|
| Placebos | 13 | 2012 | 1674 | 0.630 |
Why?
|
| Middle Aged | 119 | 2021 | 213241 | 0.630 |
Why?
|
| Premenopause | 7 | 2017 | 1033 | 0.610 |
Why?
|
| Vasomotor System | 2 | 2016 | 209 | 0.610 |
Why?
|
| Aged | 97 | 2021 | 163178 | 0.600 |
Why?
|
| Lipids | 6 | 2012 | 3307 | 0.580 |
Why?
|
| Developed Countries | 2 | 2016 | 437 | 0.570 |
Why?
|
| Carcinoma, Lobular | 2 | 2017 | 484 | 0.570 |
Why?
|
| Treatment Outcome | 49 | 2021 | 63042 | 0.560 |
Why?
|
| Receptors, Interleukin | 3 | 2016 | 245 | 0.550 |
Why?
|
| WT1 Proteins | 1 | 2017 | 178 | 0.550 |
Why?
|
| Developing Countries | 3 | 2018 | 2815 | 0.540 |
Why?
|
| Quality of Life | 25 | 2020 | 12788 | 0.530 |
Why?
|
| Diphosphonates | 4 | 2017 | 622 | 0.530 |
Why?
|
| Neoplasm Metastasis | 15 | 2018 | 4848 | 0.530 |
Why?
|
| Choristoma | 1 | 2017 | 213 | 0.520 |
Why?
|
| Estrogen Antagonists | 5 | 2009 | 151 | 0.510 |
Why?
|
| Neoplasm Staging | 20 | 2021 | 11036 | 0.510 |
Why?
|
| Musculoskeletal System | 2 | 2014 | 175 | 0.500 |
Why?
|
| Drug Costs | 2 | 2017 | 1105 | 0.500 |
Why?
|
| Vulvar Neoplasms | 1 | 2017 | 272 | 0.490 |
Why?
|
| Hyperprolactinemia | 1 | 2015 | 129 | 0.490 |
Why?
|
| Papillomavirus Infections | 2 | 2017 | 1587 | 0.490 |
Why?
|
| Immunization Programs | 1 | 2017 | 260 | 0.490 |
Why?
|
| Bone and Bones | 3 | 2012 | 2576 | 0.480 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 2017 | 386 | 0.480 |
Why?
|
| Insurance, Health | 3 | 2016 | 2492 | 0.470 |
Why?
|
| Mammary Neoplasms, Experimental | 7 | 2011 | 520 | 0.470 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2012 | 941 | 0.470 |
Why?
|
| Genes, BRCA1 | 6 | 2005 | 781 | 0.470 |
Why?
|
| Bone Density Conservation Agents | 5 | 2017 | 768 | 0.470 |
Why?
|
| Papillomaviridae | 2 | 2017 | 1119 | 0.470 |
Why?
|
| Prolactin | 1 | 2015 | 668 | 0.460 |
Why?
|
| Swainsonine | 5 | 1997 | 10 | 0.450 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2016 | 258 | 0.450 |
Why?
|
| Aged, 80 and over | 39 | 2020 | 57744 | 0.440 |
Why?
|
| Carcinoma | 2 | 2017 | 2375 | 0.440 |
Why?
|
| Ovariectomy | 8 | 2011 | 661 | 0.430 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2005 | 623 | 0.420 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2020 | 841 | 0.410 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 1995 | 1381 | 0.410 |
Why?
|
| Women's Health Services | 1 | 2012 | 93 | 0.410 |
Why?
|
| Methylnitrosourea | 3 | 2011 | 29 | 0.410 |
Why?
|
| Canada | 9 | 2014 | 2064 | 0.410 |
Why?
|
| Cervix Uteri | 1 | 2015 | 590 | 0.410 |
Why?
|
| Research Design | 7 | 2013 | 5983 | 0.400 |
Why?
|
| Adult | 82 | 2021 | 213889 | 0.400 |
Why?
|
| Aromatase | 5 | 2020 | 147 | 0.400 |
Why?
|
| Lipid Metabolism | 3 | 2011 | 1885 | 0.400 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 6539 | 0.390 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2012 | 95 | 0.380 |
Why?
|
| Lumbar Vertebrae | 6 | 2014 | 1848 | 0.380 |
Why?
|
| Neoplasm Proteins | 10 | 2021 | 3706 | 0.370 |
Why?
|
| Femur | 5 | 2009 | 1296 | 0.370 |
Why?
|
| Radiation Injuries | 2 | 2013 | 1180 | 0.360 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 581 | 0.360 |
Why?
|
| Survival Analysis | 15 | 2016 | 10251 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2017 | 5532 | 0.340 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 1023 | 0.340 |
Why?
|
| Homeodomain Proteins | 4 | 2016 | 2419 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2020 | 9944 | 0.340 |
Why?
|
| DNA, Viral | 1 | 2015 | 2226 | 0.330 |
Why?
|
| Tretinoin | 2 | 2011 | 517 | 0.330 |
Why?
|
| Mastectomy | 10 | 2017 | 1793 | 0.330 |
Why?
|
| Prognosis | 21 | 2021 | 29052 | 0.330 |
Why?
|
| Patient Selection | 6 | 2021 | 4210 | 0.330 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2008 | 390 | 0.320 |
Why?
|
| Estradiol | 14 | 2021 | 2017 | 0.320 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2012 | 300 | 0.320 |
Why?
|
| Neoadjuvant Therapy | 8 | 2017 | 2727 | 0.310 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2007 | 547 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2021 | 15518 | 0.300 |
Why?
|
| Neoplasms, Second Primary | 4 | 2008 | 1063 | 0.290 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6620 | 0.290 |
Why?
|
| Breast Neoplasms, Male | 3 | 2015 | 210 | 0.290 |
Why?
|
| Perimenopause | 2 | 2017 | 139 | 0.290 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 2794 | 0.290 |
Why?
|
| Receptors, Interleukin-17 | 5 | 2016 | 69 | 0.280 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2001 | 794 | 0.280 |
Why?
|
| Carboplatin | 5 | 2021 | 801 | 0.280 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 186 | 0.280 |
Why?
|
| Combined Modality Therapy | 12 | 2018 | 8637 | 0.280 |
Why?
|
| Hot Flashes | 3 | 2014 | 316 | 0.270 |
Why?
|
| Hodgkin Disease | 4 | 2007 | 1415 | 0.270 |
Why?
|
| Flax | 1 | 2005 | 10 | 0.260 |
Why?
|
| Incidence | 13 | 2020 | 20948 | 0.260 |
Why?
|
| Silencer Elements, Transcriptional | 1 | 2005 | 11 | 0.260 |
Why?
|
| Hypertrophy | 2 | 2021 | 569 | 0.260 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 371 | 0.260 |
Why?
|
| Primary Prevention | 2 | 2012 | 1167 | 0.260 |
Why?
|
| Testicular Neoplasms | 7 | 2000 | 803 | 0.250 |
Why?
|
| Genes, erbB-2 | 2 | 2008 | 162 | 0.250 |
Why?
|
| Vaccination | 1 | 2017 | 3275 | 0.250 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2018 | 4552 | 0.250 |
Why?
|
| Promoter Regions, Genetic | 4 | 2003 | 5867 | 0.250 |
Why?
|
| Time Factors | 17 | 2017 | 40038 | 0.240 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2018 | 25 | 0.240 |
Why?
|
| Mastectomy, Segmental | 4 | 2016 | 956 | 0.240 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5319 | 0.240 |
Why?
|
| Estrogen Receptor alpha | 5 | 2020 | 577 | 0.240 |
Why?
|
| China | 3 | 2014 | 2243 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9272 | 0.240 |
Why?
|
| Age Factors | 12 | 2018 | 18355 | 0.230 |
Why?
|
| Bone Resorption | 2 | 2007 | 722 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2011 | 8300 | 0.230 |
Why?
|
| Transcription Factors | 10 | 2005 | 12209 | 0.230 |
Why?
|
| Menopause | 12 | 2020 | 1626 | 0.230 |
Why?
|
| Proportional Hazards Models | 8 | 2017 | 12354 | 0.230 |
Why?
|
| Germinoma | 4 | 2000 | 134 | 0.230 |
Why?
|
| Progesterone | 1 | 2008 | 773 | 0.230 |
Why?
|
| Brazil | 4 | 2020 | 1264 | 0.230 |
Why?
|
| Phytotherapy | 1 | 2005 | 298 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 8430 | 0.220 |
Why?
|
| Rats | 15 | 2011 | 24250 | 0.220 |
Why?
|
| Cause of Death | 2 | 2016 | 3580 | 0.210 |
Why?
|
| Radiotherapy | 4 | 2012 | 1533 | 0.210 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 39001 | 0.210 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1900 | 0.210 |
Why?
|
| Postpartum Period | 2 | 2021 | 1086 | 0.210 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 3057 | 0.210 |
Why?
|
| Bone Neoplasms | 3 | 2011 | 2529 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2013 | 629 | 0.190 |
Why?
|
| Introns | 2 | 2001 | 991 | 0.190 |
Why?
|
| Paclitaxel | 2 | 2017 | 1705 | 0.190 |
Why?
|
| Quality of Health Care | 2 | 2016 | 4370 | 0.190 |
Why?
|
| Ifosfamide | 5 | 1995 | 228 | 0.190 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 4839 | 0.190 |
Why?
|
| Palliative Care | 4 | 2020 | 3490 | 0.190 |
Why?
|
| Colombia | 1 | 2021 | 258 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2014 | 3155 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2015 | 10940 | 0.180 |
Why?
|
| Recurrence | 5 | 2016 | 8337 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2020 | 5170 | 0.180 |
Why?
|
| Cholesterol | 3 | 2012 | 2922 | 0.180 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2006 | 60 | 0.170 |
Why?
|
| Megestrol Acetate | 1 | 1999 | 18 | 0.170 |
Why?
|
| Survival Rate | 13 | 2007 | 12786 | 0.170 |
Why?
|
| Aniline Compounds | 2 | 2014 | 986 | 0.170 |
Why?
|
| Risk Factors | 20 | 2018 | 72252 | 0.170 |
Why?
|
| Quinolines | 2 | 2014 | 732 | 0.170 |
Why?
|
| BRCA1 Protein | 4 | 2021 | 1148 | 0.170 |
Why?
|
| Minority Groups | 1 | 2006 | 1222 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 4 | 2020 | 1676 | 0.160 |
Why?
|
| Organ Size | 3 | 2011 | 2241 | 0.160 |
Why?
|
| Animals | 34 | 2017 | 168660 | 0.160 |
Why?
|
| INDEL Mutation | 1 | 2019 | 279 | 0.160 |
Why?
|
| Disease Progression | 11 | 2017 | 13273 | 0.150 |
Why?
|
| Genes, Homeobox | 1 | 1999 | 286 | 0.150 |
Why?
|
| Bone Remodeling | 3 | 2007 | 569 | 0.150 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 1783 | 0.150 |
Why?
|
| Lung Neoplasms | 8 | 2018 | 13112 | 0.150 |
Why?
|
| Cisplatin | 6 | 2015 | 1662 | 0.140 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 275 | 0.140 |
Why?
|
| Prospective Studies | 16 | 2020 | 53250 | 0.140 |
Why?
|
| Etoposide | 7 | 1995 | 641 | 0.140 |
Why?
|
| Epirubicin | 2 | 1998 | 80 | 0.140 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 262 | 0.140 |
Why?
|
| Genes, p53 | 2 | 2021 | 755 | 0.140 |
Why?
|
| Piperidines | 1 | 2004 | 1601 | 0.140 |
Why?
|
| Acetic Acid | 1 | 2015 | 55 | 0.140 |
Why?
|
| Risk Assessment | 11 | 2018 | 23327 | 0.140 |
Why?
|
| Secondary Prevention | 2 | 2016 | 1529 | 0.140 |
Why?
|
| Lymph Node Excision | 2 | 1999 | 1262 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2011 | 729 | 0.130 |
Why?
|
| Models, Genetic | 2 | 2011 | 3492 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2015 | 6593 | 0.130 |
Why?
|
| Collagen Type I | 2 | 2011 | 592 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 3591 | 0.130 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 7719 | 0.130 |
Why?
|
| Alkaline Phosphatase | 2 | 2011 | 866 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 1213 | 0.130 |
Why?
|
| Caribbean Region | 1 | 2015 | 194 | 0.130 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 348 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 523 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 12243 | 0.130 |
Why?
|
| Indicators and Reagents | 1 | 2015 | 462 | 0.130 |
Why?
|
| Allied Health Personnel | 1 | 2016 | 162 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2017 | 371 | 0.120 |
Why?
|
| Endometrial Neoplasms | 2 | 2018 | 1350 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1998 | 604 | 0.120 |
Why?
|
| Bones of Lower Extremity | 1 | 2014 | 6 | 0.120 |
Why?
|
| Fractures, Bone | 3 | 2014 | 1946 | 0.120 |
Why?
|
| Carbohydrate Metabolism | 1 | 1995 | 264 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 2017 | 420 | 0.120 |
Why?
|
| Molecular Sequence Data | 9 | 2005 | 18107 | 0.120 |
Why?
|
| Base Sequence | 8 | 2005 | 12798 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2016 | 2453 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4749 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 2037 | 0.120 |
Why?
|
| Genotype | 7 | 2020 | 12944 | 0.120 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2014 | 71 | 0.120 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 15142 | 0.120 |
Why?
|
| Cohort Studies | 9 | 2021 | 40545 | 0.120 |
Why?
|
| Gene Silencing | 1 | 2000 | 1537 | 0.120 |
Why?
|
| West Indies | 1 | 2013 | 34 | 0.110 |
Why?
|
| Economic Development | 1 | 2014 | 69 | 0.110 |
Why?
|
| Lymphatic Metastasis | 6 | 2016 | 2924 | 0.110 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 1725 | 0.110 |
Why?
|
| Arthralgia | 1 | 2017 | 456 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2007 | 18027 | 0.110 |
Why?
|
| Russia | 1 | 2014 | 408 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 7 | 2003 | 6311 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 685 | 0.110 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 329 | 0.110 |
Why?
|
| Mass Screening | 4 | 2020 | 5251 | 0.110 |
Why?
|
| Urban Health Services | 1 | 2014 | 179 | 0.110 |
Why?
|
| Environmental Pollution | 1 | 2014 | 118 | 0.110 |
Why?
|
| Receptors, Steroid | 2 | 2017 | 155 | 0.110 |
Why?
|
| Vitamin D | 4 | 2017 | 3222 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2011 | 2017 | 0.110 |
Why?
|
| DNA-Binding Proteins | 5 | 2003 | 9648 | 0.110 |
Why?
|
| Aminoglutethimide | 5 | 1986 | 15 | 0.110 |
Why?
|
| Vaginal Smears | 1 | 2015 | 511 | 0.110 |
Why?
|
| Cultural Characteristics | 1 | 2014 | 261 | 0.110 |
Why?
|
| History, 18th Century | 1 | 2013 | 213 | 0.110 |
Why?
|
| Drug Eruptions | 1 | 2015 | 297 | 0.110 |
Why?
|
| Signal Transduction | 5 | 2016 | 23398 | 0.110 |
Why?
|
| Case-Control Studies | 10 | 2020 | 21733 | 0.100 |
Why?
|
| Mental Health | 3 | 2006 | 3012 | 0.100 |
Why?
|
| Pain | 4 | 2019 | 4987 | 0.100 |
Why?
|
| Drug Evaluation | 6 | 1997 | 647 | 0.100 |
Why?
|
| Survival | 1 | 2012 | 163 | 0.100 |
Why?
|
| Retrospective Studies | 15 | 2019 | 77410 | 0.100 |
Why?
|
| Estrone | 3 | 2021 | 240 | 0.100 |
Why?
|
| alpha-Mannosidase | 3 | 1997 | 20 | 0.100 |
Why?
|
| Mannosidases | 3 | 1997 | 22 | 0.100 |
Why?
|
| Weight Gain | 2 | 2017 | 2294 | 0.100 |
Why?
|
| Public Sector | 1 | 2013 | 265 | 0.100 |
Why?
|
| Genome-Wide Association Study | 9 | 2021 | 12259 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 973 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 948 | 0.100 |
Why?
|
| Gene Expression Regulation | 5 | 2018 | 12066 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3503 | 0.100 |
Why?
|
| Chemokines | 1 | 2016 | 968 | 0.100 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 336 | 0.100 |
Why?
|
| BRCA2 Protein | 5 | 2015 | 794 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 612 | 0.100 |
Why?
|
| Administration, Oral | 6 | 2005 | 3912 | 0.100 |
Why?
|
| Comorbidity | 4 | 2016 | 10380 | 0.100 |
Why?
|
| Health Resources | 1 | 2017 | 912 | 0.100 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 15 | 0.090 |
Why?
|
| Sarcoma, Kaposi | 2 | 1991 | 370 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2017 | 2500 | 0.090 |
Why?
|
| Isoenzymes | 3 | 2004 | 1728 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2021 | 17439 | 0.090 |
Why?
|
| Health Services Research | 1 | 2018 | 1836 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 441 | 0.090 |
Why?
|
| Medroxyprogesterone | 2 | 1989 | 37 | 0.090 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 3 | 2007 | 361 | 0.090 |
Why?
|
| Private Sector | 1 | 2013 | 393 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2020 | 7880 | 0.090 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2010 | 89 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15281 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2018 | 1917 | 0.090 |
Why?
|
| Rural Health Services | 1 | 2014 | 380 | 0.090 |
Why?
|
| Femur Neck | 1 | 2012 | 309 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2014 | 3292 | 0.090 |
Why?
|
| Glycoproteins | 2 | 1995 | 2266 | 0.090 |
Why?
|
| Lymphoma | 1 | 1999 | 1875 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 2010 | 127 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 2850 | 0.090 |
Why?
|
| Octreotide | 3 | 2016 | 146 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2010 | 299 | 0.090 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2021 | 298 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5388 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 7270 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 1995 | 1275 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2015 | 1382 | 0.090 |
Why?
|
| Calcium | 2 | 2014 | 5755 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2649 | 0.090 |
Why?
|
| Male | 37 | 2019 | 349776 | 0.090 |
Why?
|
| Health Care Costs | 2 | 2013 | 3207 | 0.090 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 401 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2013 | 606 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2015 | 1146 | 0.090 |
Why?
|
| Models, Organizational | 1 | 2013 | 574 | 0.090 |
Why?
|
| Cell Size | 1 | 2011 | 641 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 7784 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2007 | 1660 | 0.080 |
Why?
|
| Social Support | 1 | 2019 | 2118 | 0.080 |
Why?
|
| Mitoxantrone | 4 | 2000 | 152 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 1411 | 0.080 |
Why?
|
| Oligosaccharides | 3 | 1997 | 415 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1988 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2000 | 3024 | 0.080 |
Why?
|
| Health Services | 1 | 2014 | 758 | 0.080 |
Why?
|
| Doxorubicin | 4 | 2000 | 2234 | 0.080 |
Why?
|
| Survivors | 2 | 2010 | 2291 | 0.080 |
Why?
|
| Pyrrolidines | 1 | 2010 | 341 | 0.080 |
Why?
|
| Antibodies | 1 | 2017 | 2459 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1888 | 0.080 |
Why?
|
| Compressive Strength | 1 | 2009 | 169 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 3617 | 0.080 |
Why?
|
| Biopsy | 4 | 2017 | 6750 | 0.080 |
Why?
|
| Response Elements | 3 | 2018 | 312 | 0.080 |
Why?
|
| Social Stigma | 1 | 2014 | 701 | 0.080 |
Why?
|
| India | 1 | 2014 | 2200 | 0.080 |
Why?
|
| Mutation | 9 | 2021 | 29777 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2012 | 575 | 0.070 |
Why?
|
| Vinblastine | 2 | 2000 | 501 | 0.070 |
Why?
|
| Gene Expression | 2 | 1999 | 7793 | 0.070 |
Why?
|
| Chromatography, Thin Layer | 3 | 2005 | 223 | 0.070 |
Why?
|
| Poverty | 1 | 2018 | 2660 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2006 | 8316 | 0.070 |
Why?
|
| Pregnancy | 3 | 2021 | 29140 | 0.070 |
Why?
|
| Data Mining | 1 | 2011 | 537 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 15067 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2008 | 1938 | 0.070 |
Why?
|
| Peptides | 2 | 2011 | 4406 | 0.070 |
Why?
|
| Procollagen | 1 | 2007 | 185 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2018 | 2063 | 0.070 |
Why?
|
| Chemoprevention | 2 | 2020 | 319 | 0.070 |
Why?
|
| Alleles | 2 | 2015 | 6934 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3769 | 0.070 |
Why?
|
| Risk | 3 | 2013 | 9677 | 0.070 |
Why?
|
| Injections, Intramuscular | 4 | 2004 | 553 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 1151 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2008 | 1970 | 0.070 |
Why?
|
| Goserelin | 1 | 2006 | 129 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3530 | 0.070 |
Why?
|
| Ontario | 3 | 2006 | 383 | 0.070 |
Why?
|
| Apoptosis | 3 | 2011 | 9718 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 6487 | 0.060 |
Why?
|
| Cholesterol, LDL | 2 | 2005 | 2354 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 1999 | 403 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2016 | 3476 | 0.060 |
Why?
|
| Data Collection | 1 | 2014 | 3339 | 0.060 |
Why?
|
| Hip Joint | 1 | 2012 | 1002 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1991 | 2232 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 3 | 1992 | 420 | 0.060 |
Why?
|
| Adolescent | 7 | 2020 | 85729 | 0.060 |
Why?
|
| Bile | 1 | 1986 | 299 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 81 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 1171 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2013 | 1161 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 300 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 626 | 0.060 |
Why?
|
| Health Policy | 1 | 2017 | 2662 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2002 | 2617 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 16674 | 0.060 |
Why?
|
| Osteocalcin | 1 | 2004 | 273 | 0.060 |
Why?
|
| Young Adult | 3 | 2015 | 56392 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 1770 | 0.060 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 933 | 0.060 |
Why?
|
| Sample Size | 1 | 2007 | 841 | 0.060 |
Why?
|
| Neutropenia | 5 | 2000 | 895 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2000 | 1524 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2013 | 1261 | 0.060 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 1684 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 1998 | 690 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2012 | 1813 | 0.060 |
Why?
|
| Alcoholism | 1 | 2014 | 1907 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3677 | 0.060 |
Why?
|
| Binding Sites | 3 | 2003 | 6111 | 0.060 |
Why?
|
| Remission Induction | 4 | 1994 | 2384 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 2281 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2007 | 1586 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 644 | 0.050 |
Why?
|
| Nuclear Proteins | 3 | 2005 | 5854 | 0.050 |
Why?
|
| Radiography | 1 | 2014 | 7010 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1999 | 1097 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2015 | 9440 | 0.050 |
Why?
|
| Protein Binding | 3 | 2016 | 9377 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 1161 | 0.050 |
Why?
|
| Markov Chains | 1 | 2006 | 968 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 890 | 0.050 |
Why?
|
| Heterozygote | 4 | 2015 | 2803 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 19894 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 2029 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2050 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2013 | 1796 | 0.050 |
Why?
|
| Patient Compliance | 2 | 2017 | 2683 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 708 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 11360 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2005 | 572 | 0.050 |
Why?
|
| Cell Line | 7 | 2018 | 15993 | 0.050 |
Why?
|
| Probability | 2 | 2005 | 2505 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2017 | 4437 | 0.050 |
Why?
|
| United States | 5 | 2014 | 69859 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3308 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 12718 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 4803 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2004 | 601 | 0.050 |
Why?
|
| Logistic Models | 2 | 2013 | 13404 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 1156 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2007 | 1018 | 0.050 |
Why?
|
| Jews | 2 | 1999 | 385 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2003 | 2942 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 2944 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 376 | 0.050 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2020 | 27 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2007 | 1640 | 0.050 |
Why?
|
| Progestins | 1 | 2002 | 306 | 0.050 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 1608 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 1376 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2010 | 3690 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 128 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2004 | 1894 | 0.040 |
Why?
|
| Nomograms | 1 | 2021 | 228 | 0.040 |
Why?
|
| Prednisone | 2 | 1995 | 1574 | 0.040 |
Why?
|
| Carbohydrate Sequence | 2 | 1997 | 414 | 0.040 |
Why?
|
| Plasmids | 1 | 2005 | 2308 | 0.040 |
Why?
|
| POU Domain Factors | 1 | 1999 | 46 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2007 | 2614 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1999 | 378 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1794 | 0.040 |
Why?
|
| Steroids | 1 | 2004 | 930 | 0.040 |
Why?
|
| Cushing Syndrome | 2 | 1992 | 249 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 1999 | 388 | 0.040 |
Why?
|
| Cell Survival | 2 | 2007 | 5881 | 0.040 |
Why?
|
| Palpation | 1 | 1999 | 167 | 0.040 |
Why?
|
| Models, Biological | 2 | 2006 | 9582 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2021 | 10477 | 0.040 |
Why?
|
| Edema | 2 | 1997 | 789 | 0.040 |
Why?
|
| Pyridines | 1 | 2010 | 2827 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 749 | 0.040 |
Why?
|
| Amino Acids | 1 | 2004 | 1733 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 603 | 0.040 |
Why?
|
| Fluorouracil | 3 | 2000 | 1619 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1639 | 0.040 |
Why?
|
| DNA | 4 | 2015 | 7295 | 0.040 |
Why?
|
| Pedigree | 3 | 1997 | 4643 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2007 | 2110 | 0.040 |
Why?
|
| DNA Primers | 2 | 2000 | 2891 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 589 | 0.040 |
Why?
|
| Body Weight | 1 | 2009 | 4670 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1999 | 1085 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2013 | 3750 | 0.040 |
Why?
|
| Verapamil | 1 | 1998 | 244 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 460 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 878 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 205 | 0.040 |
Why?
|
| DNA Repair | 2 | 1998 | 2045 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1999 | 349 | 0.040 |
Why?
|
| Carbohydrate Conformation | 1 | 1997 | 209 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 35409 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 5752 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2017 | 203 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2003 | 5179 | 0.040 |
Why?
|
| Smoking | 1 | 2014 | 8984 | 0.040 |
Why?
|
| DNA, Neoplasm | 3 | 1997 | 1758 | 0.040 |
Why?
|
| Cytokines | 1 | 2012 | 7324 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 2715 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2016 | 2615 | 0.040 |
Why?
|
| Loss of Heterozygosity | 2 | 2015 | 684 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 705 | 0.040 |
Why?
|
| Risk Management | 1 | 2000 | 571 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 1800 | 0.040 |
Why?
|
| Axilla | 1 | 1999 | 597 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 713 | 0.030 |
Why?
|
| Fatigue | 1 | 2003 | 1530 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2000 | 4320 | 0.030 |
Why?
|
| X Chromosome | 1 | 2000 | 814 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 674 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2021 | 850 | 0.030 |
Why?
|
| Physicians | 1 | 2014 | 4569 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2000 | 2274 | 0.030 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2010 | 546 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6485 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 215 | 0.030 |
Why?
|
| Dexamethasone | 2 | 1995 | 1950 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 1997 | 261 | 0.030 |
Why?
|
| Hypertension | 1 | 2016 | 8480 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2000 | 1545 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 1997 | 418 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 1996 | 173 | 0.030 |
Why?
|
| Bleomycin | 1 | 1996 | 512 | 0.030 |
Why?
|
| Transfection | 2 | 2003 | 5892 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 1013 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 370 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1999 | 2327 | 0.030 |
Why?
|
| Vagina | 1 | 2020 | 825 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2016 | 4326 | 0.030 |
Why?
|
| Glycosylation | 2 | 1995 | 1129 | 0.030 |
Why?
|
| Doxycycline | 1 | 1996 | 326 | 0.030 |
Why?
|
| Melphalan | 1 | 1977 | 431 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 3645 | 0.030 |
Why?
|
| Proteins | 2 | 2001 | 6098 | 0.030 |
Why?
|
| Life Style | 1 | 2006 | 3833 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 2375 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1999 | 710 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 1996 | 247 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 2839 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1999 | 1396 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1422 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2001 | 1203 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 6773 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 3020 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2007 | 5096 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2003 | 3128 | 0.030 |
Why?
|
| Luteinizing Hormone | 2 | 1995 | 867 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1995 | 323 | 0.030 |
Why?
|
| HeLa Cells | 2 | 1999 | 3130 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6363 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 1222 | 0.030 |
Why?
|
| DNA Replication | 1 | 2000 | 1399 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1993 | 102 | 0.030 |
Why?
|
| Genome, Human | 2 | 2021 | 4418 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2017 | 3680 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2006 | 2789 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 1787 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2963 | 0.030 |
Why?
|
| Diclofenac | 1 | 2013 | 71 | 0.030 |
Why?
|
| Haplotypes | 1 | 2019 | 2779 | 0.030 |
Why?
|
| Pyridones | 1 | 2017 | 711 | 0.030 |
Why?
|
| Naproxen | 1 | 2013 | 99 | 0.030 |
Why?
|
| Seminoma | 1 | 1994 | 139 | 0.030 |
Why?
|
| Safety | 1 | 1997 | 1184 | 0.030 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2012 | 11 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1995 | 745 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2015 | 3585 | 0.030 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 1994 | 410 | 0.030 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 1992 | 30 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 1999 | 694 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2000 | 5445 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 1999 | 1578 | 0.030 |
Why?
|
| Liver Neoplasms | 2 | 2006 | 4251 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 3608 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2000 | 2749 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2003 | 2267 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 2865 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2013 | 236 | 0.020 |
Why?
|
| Chromosome Mapping | 3 | 2010 | 4737 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1999 | 13809 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2000 | 1066 | 0.020 |
Why?
|
| Family Health | 2 | 1999 | 1280 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1976 | 1060 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1977 | 1351 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1994 | 423 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1781 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2015 | 695 | 0.020 |
Why?
|
| Mice | 8 | 2003 | 81154 | 0.020 |
Why?
|
| Point Mutation | 1 | 1996 | 1623 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2021 | 4026 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1994 | 340 | 0.020 |
Why?
|
| DNA Damage | 1 | 2000 | 2429 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1995 | 501 | 0.020 |
Why?
|
| Drug Design | 1 | 1995 | 1075 | 0.020 |
Why?
|
| Aldosterone | 1 | 1995 | 877 | 0.020 |
Why?
|
| C-Peptide | 1 | 2011 | 420 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20121 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3547 | 0.020 |
Why?
|
| North America | 1 | 1993 | 1249 | 0.020 |
Why?
|
| Stroke | 2 | 2013 | 9975 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2012 | 577 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 1989 | 163 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1994 | 1663 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3583 | 0.020 |
Why?
|
| Hydrocortisone | 2 | 1995 | 1826 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2003 | 4041 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2504 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1999 | 6457 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 2000 | 2241 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1999 | 1642 | 0.020 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2008 | 33 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2012 | 435 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 40964 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1986 | 2184 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6170 | 0.020 |
Why?
|
| Androgens | 1 | 1995 | 1247 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1996 | 2764 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2013 | 1124 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1656 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2000 | 5021 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 814 | 0.020 |
Why?
|
| Diet | 1 | 2005 | 7930 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1996 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 916 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 376 | 0.020 |
Why?
|
| Algorithms | 1 | 2006 | 13869 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 902 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1994 | 895 | 0.020 |
Why?
|
| Autoradiography | 2 | 1997 | 745 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 1986 | 251 | 0.020 |
Why?
|
| Ultrasonography, Mammary | 1 | 2007 | 250 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 4925 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2938 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2000 | 4245 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 1356 | 0.020 |
Why?
|
| Colorimetry | 1 | 1985 | 147 | 0.020 |
Why?
|
| Biological Availability | 1 | 2005 | 397 | 0.020 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2003 | 27 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1993 | 2453 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1985 | 1574 | 0.010 |
Why?
|
| Biological Assay | 1 | 2007 | 650 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1992 | 2951 | 0.010 |
Why?
|
| Autoantigens | 1 | 2008 | 892 | 0.010 |
Why?
|
| Melanoma | 3 | 1977 | 5508 | 0.010 |
Why?
|
| Odds Ratio | 2 | 2010 | 9848 | 0.010 |
Why?
|
| Women's Health | 1 | 2013 | 2033 | 0.010 |
Why?
|
| Adipocytes | 1 | 2010 | 1182 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1997 | 2736 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 290 | 0.010 |
Why?
|
| Retinal Dehydrogenase | 1 | 2003 | 74 | 0.010 |
Why?
|
| Respiration Disorders | 1 | 1986 | 371 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 735 | 0.010 |
Why?
|
| Patient Advocacy | 1 | 2005 | 353 | 0.010 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2003 | 223 | 0.010 |
Why?
|
| Child | 2 | 2021 | 77637 | 0.010 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2003 | 142 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 1992 | 5230 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2005 | 601 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2003 | 166 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 897 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 1102 | 0.010 |
Why?
|
| Age of Onset | 2 | 1999 | 3268 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 2000 | 142 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 2000 | 141 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4221 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2000 | 190 | 0.010 |
Why?
|
| Polyploidy | 1 | 2000 | 114 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2000 | 277 | 0.010 |
Why?
|
| Temperature | 2 | 1977 | 2202 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2000 | 438 | 0.010 |
Why?
|
| District of Columbia | 1 | 1999 | 157 | 0.010 |
Why?
|
| Bone Diseases, Developmental | 1 | 2000 | 130 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 365 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2000 | 719 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 1723 | 0.010 |
Why?
|
| Lod Score | 1 | 2000 | 613 | 0.010 |
Why?
|
| Founder Effect | 1 | 1999 | 189 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2883 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1999 | 878 | 0.010 |
Why?
|
| Informed Consent | 1 | 2005 | 995 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 7172 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1993 | 10179 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2013 | 6078 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4974 | 0.010 |
Why?
|
| Inflammation | 1 | 2017 | 10629 | 0.010 |
Why?
|
| Software | 1 | 2011 | 4440 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 251 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 1996 | 5033 | 0.010 |
Why?
|
| Family | 2 | 2000 | 3144 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1999 | 799 | 0.010 |
Why?
|
| Insulin | 1 | 2011 | 6584 | 0.010 |
Why?
|
| Radiation Effects | 1 | 1976 | 68 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1997 | 427 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 1952 | 0.010 |
Why?
|
| Sclerosis | 1 | 1996 | 213 | 0.010 |
Why?
|
| Cardiography, Impedance | 1 | 1996 | 41 | 0.010 |
Why?
|
| Thymine | 1 | 1976 | 68 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 335 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 3000 | 0.010 |
Why?
|
| Fibroblasts | 2 | 1977 | 4162 | 0.010 |
Why?
|
| Half-Life | 2 | 1987 | 660 | 0.010 |
Why?
|
| Guanine | 1 | 1997 | 274 | 0.010 |
Why?
|
| Cytosine | 1 | 1997 | 216 | 0.010 |
Why?
|
| Neck | 1 | 2000 | 698 | 0.010 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1996 | 104 | 0.010 |
Why?
|
| France | 1 | 1996 | 517 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11478 | 0.010 |
Why?
|
| Kinetics | 3 | 1987 | 6476 | 0.010 |
Why?
|
| Codon | 1 | 1996 | 611 | 0.010 |
Why?
|
| Aging | 1 | 1993 | 8655 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1994 | 156 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 6380 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1996 | 468 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2000 | 2634 | 0.010 |
Why?
|
| RNA Viruses | 1 | 1974 | 124 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 803 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15526 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 5973 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1992 | 101 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1178 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4031 | 0.010 |
Why?
|
| Ketoconazole | 1 | 1992 | 95 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 11708 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14714 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1993 | 1581 | 0.010 |
Why?
|
| Ovary | 2 | 1986 | 980 | 0.010 |
Why?
|
| Adenine | 1 | 1997 | 935 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1977 | 1374 | 0.010 |
Why?
|
| Acetylation | 1 | 1994 | 1084 | 0.010 |
Why?
|
| Decision Making | 1 | 2005 | 3887 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2000 | 13028 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 6976 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 1994 | 560 | 0.010 |
Why?
|
| Liver | 1 | 1986 | 7479 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 2438 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 1996 | 1265 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 3463 | 0.010 |
Why?
|
| Pro-Opiomelanocortin | 1 | 1989 | 163 | 0.010 |
Why?
|
| Vomiting | 1 | 1992 | 636 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1992 | 902 | 0.000 |
Why?
|
| Mass Spectrometry | 2 | 1986 | 2203 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1989 | 648 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1996 | 4183 | 0.000 |
Why?
|
| Danazol | 1 | 1986 | 42 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1989 | 664 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1989 | 389 | 0.000 |
Why?
|
| Dihydrotestosterone | 1 | 1986 | 185 | 0.000 |
Why?
|
| Interferon Type I | 1 | 1989 | 541 | 0.000 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1994 | 1986 | 0.000 |
Why?
|
| Leukemia | 1 | 1994 | 1509 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2000 | 14563 | 0.000 |
Why?
|
| Castration | 1 | 1984 | 158 | 0.000 |
Why?
|
| Biotransformation | 1 | 1983 | 168 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1989 | 1531 | 0.000 |
Why?
|
| Cells, Cultured | 2 | 1977 | 19232 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1983 | 475 | 0.000 |
Why?
|
| Rabbits | 1 | 1986 | 4894 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1986 | 2375 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 5264 | 0.000 |
Why?
|
| Rauscher Virus | 1 | 1974 | 31 | 0.000 |
Why?
|
| Friend murine leukemia virus | 1 | 1974 | 65 | 0.000 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1989 | 3142 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1974 | 313 | 0.000 |
Why?
|
| Thymidine | 1 | 1974 | 310 | 0.000 |
Why?
|
| Tritium | 1 | 1974 | 745 | 0.000 |
Why?
|
| Uridine | 1 | 1974 | 146 | 0.000 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1974 | 193 | 0.000 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1974 | 248 | 0.000 |
Why?
|
| Inclusion Bodies | 1 | 1974 | 279 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1989 | 4260 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1974 | 2646 | 0.000 |
Why?
|
| Cerebellar Neoplasms | 1 | 1974 | 587 | 0.000 |
Why?
|
| Spleen | 1 | 1974 | 2359 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1974 | 2901 | 0.000 |
Why?
|